Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial

Published:2023-05 Issue: Volume:34 Page:100731
ISSN:2666-6065
Container-title:The Lancet Regional Health - Western Pacific
language:en
Short-container-title:The Lancet Regional Health - Western Pacific

Author:

Chu Kai,Bi Zhao-Feng,Huang Wei-Jin,Li Ya-Fei,Zhang Li,Yang Chang-Lin,Jiang Han-Min,Zang Xia,Chen Qi,Liu Dong-Lin,Pan Hong-Xing,Huang Yue,Zheng Feng-Zhu,Zhang Qiu-Fen,Sun Guang,Su Ying-Ying,Huang Shou-Jie,Pan Hui-Rong,Wu Ting^ORCID,Hu Yue-Mei,Zhang Jun^ORCID,Zhu Feng-Cai,Xia Ning-Shao

Publisher

Elsevier BV

Subject

Infectious Diseases,Psychiatry and Mental health,Geriatrics and Gerontology,Public Health, Environmental and Occupational Health,Obstetrics and Gynecology,Health Policy,Pediatrics, Perinatology and Child Health,Internal Medicine

Reference18 articles.

1. Worldwide burden of cancer attributable to HPV by site, country and HPV type;de Martel;Int J Cancer,2017

2. Genital warts: a comprehensive review;Yanofsky;J Clin Aesthet Dermatol,2012

3. Human papillomavirus and related diseases report;Bruni,2021

4. Chapter 10 - low-risk human papillomavirus: genital warts, cancer and respiratory papillomatosis;Lacey,2020

5. Electronic address swi. Human papillomavirus vaccines: WHO position paper (2022 update);World Health Organization;Wkly Epidemiol Rec,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial;The Lancet Infectious Diseases;2023-11

2. Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial;Science Bulletin;2023-10